Are Adverse Outcome Pathways Here to Stay?
Author(s) -
Natàlia GarcíaReyero
Publication year - 2014
Publication title -
environmental science and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.851
H-Index - 397
eISSN - 1520-5851
pISSN - 0013-936X
DOI - 10.1021/es504976d
Subject(s) - adverse outcome pathway , outcome (game theory) , adverse effect , medicine , intensive care medicine , pharmacology , computational biology , biology , economics , mathematical economics
Social pressure to minimize the use of animal testing and the ever-increasing concern on animal welfare, together with the need for more human-relevant and more predictive toxicity tests, are some of the drivers for new approaches to chemical screening. These approaches must also be able to accelerate the screening and assessment of the thousands of chemicals that are currently in use and in development for potential hazards to human and ecological health. Ideally, approaches are needed that decrease (or eliminate) animal testing while increasing predictivity. Efforts in many countries have focused on a toxicological pathway-based vision for human health assessments relying on in vitro systems and predictive models,1 vision equally applicable to ecological risk assessment.2 A pathway-based analysis of chemical effects opens numerous opportunities to apply nontraditional approaches for understanding the risks of chemical exposure. Conservation of molecular initiating and key events leading to adverse outcomes of regulatory concern provide a defensible framework for extrapolating chemical effects across species, even if the specific adverse outcomes differ between them.3.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom